| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-vascular endothelial growth factor therapy in the era of personalized medicine
|
Féliz, Luis R.
|
|
2013
|
72 |
1 |
p. 1-12
|
artikel
|
| 2 |
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
|
Agelaki, S.
|
|
2013
|
72 |
1 |
p. 45-51
|
artikel
|
| 3 |
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder
|
Eroglu, Zeynep
|
|
2013
|
72 |
1 |
p. 263-267
|
artikel
|
| 4 |
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma
|
Abaid, Lisa N.
|
|
2013
|
72 |
1 |
p. 101-107
|
artikel
|
| 5 |
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
|
Iqbal, Syma
|
|
2013
|
72 |
1 |
p. 85-91
|
artikel
|
| 6 |
Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry
|
Lin, T.-H.
|
|
2013
|
72 |
1 |
p. 181-188
|
artikel
|
| 7 |
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
|
Han, T. H.
|
|
2013
|
72 |
1 |
p. 241-249
|
artikel
|
| 8 |
Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience
|
Jo, Jae-Cheol
|
|
2013
|
72 |
1 |
p. 201-207
|
artikel
|
| 9 |
Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer
|
Takebayashi, Katsushi
|
|
2013
|
72 |
1 |
p. 217-222
|
artikel
|
| 10 |
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells
|
Liu, Huaping
|
|
2013
|
72 |
1 |
p. 251-262
|
artikel
|
| 11 |
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography
|
Osawa, Gakuji
|
|
2013
|
72 |
1 |
p. 209-215
|
artikel
|
| 12 |
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues
|
Patel, Krupa J.
|
|
2013
|
72 |
1 |
p. 127-138
|
artikel
|
| 13 |
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
|
Dosso, Sara De
|
|
2013
|
72 |
1 |
p. 159-165
|
artikel
|
| 14 |
Erratum to: Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
|
Du, Gangjun
|
|
2013
|
72 |
1 |
p. 275
|
artikel
|
| 15 |
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
|
Kim, Ji-Won
|
|
2013
|
72 |
1 |
p. 109-115
|
artikel
|
| 16 |
Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view
|
Mas-Fuster, Maria Isabel
|
|
2013
|
72 |
1 |
p. 273-274
|
artikel
|
| 17 |
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
|
Romiti, Adriana
|
|
2013
|
72 |
1 |
p. 13-33
|
artikel
|
| 18 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model
|
Grossman, Rachel
|
|
2013
|
72 |
1 |
p. 93-100
|
artikel
|
| 19 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1
|
Wang, Jie
|
|
2013
|
72 |
1 |
p. 147-158
|
artikel
|
| 20 |
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
|
Bonate, Peter L.
|
|
2013
|
72 |
1 |
p. 231-240
|
artikel
|
| 21 |
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination
|
Tentori, Lucio
|
|
2013
|
72 |
1 |
p. 117-125
|
artikel
|
| 22 |
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
|
Patel, Atish
|
|
2013
|
72 |
1 |
p. 189-199
|
artikel
|
| 23 |
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma
|
Noda, Satoshi
|
|
2013
|
72 |
1 |
p. 269-272
|
artikel
|
| 24 |
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
|
Stephenson, Christopher M.
|
|
2013
|
72 |
1 |
p. 139-146
|
artikel
|
| 25 |
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
|
Salazar, R.
|
|
|
72 |
1 |
p. 75-83
|
artikel
|
| 26 |
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
|
Salazar, R.
|
|
2013
|
72 |
1 |
p. 75-83
|
artikel
|
| 27 |
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors
|
Thai, Hoai-Thu
|
|
2013
|
72 |
1 |
p. 167-180
|
artikel
|
| 28 |
Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study
|
Lavau-Denes, Sandrine
|
|
2013
|
72 |
1 |
p. 65-73
|
artikel
|
| 29 |
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
|
Ji, Jun Ho
|
|
2013
|
72 |
1 |
p. 223-230
|
artikel
|
| 30 |
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
|
Shi, Min
|
|
2013
|
72 |
1 |
p. 35-44
|
artikel
|
| 31 |
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
|
El-Khoueiry, Anthony
|
|
2013
|
72 |
1 |
p. 53-64
|
artikel
|
Tijdschrift beschrijving